TOVX
Theriva Biologics, Inc.
$0.24
-0.01 (-5.84%)
At close · Jul 7
Market Cap
$10.80M
Shares
45,892,668
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2011
Net Income
-$23.74M
+7.5%
FY2025
Diluted EPS
-$2.08
+89.1%
FY2025
Operating Cash Flow
-$16.67M
+1.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $2.61M | |
| $5.99M | $8.6M | $12.03M | $14.31M | $11.72M | $7.8M | $5.13M | $11.08M | $11.84M | $18.78M | $29.11M | $32.91M | $14.49M | $6.51M | $12.29M | $3.34M | $1.58M | |
| $16.07M | $15.45M | $7.4M | $7.12M | $9.86M | $6.47M | $5.03M | $4.58M | $5.73M | $7.47M | $10.14M | $8.07M | $6.01M | $5.83M | $5.01M | $2.59M | $2.12M | |
| — | $108K | $137K | $135K | $85K | $87K | $201K | $240K | $272K | $245K | $157K | $72K | $20K | $43K | — | — | — | |
| $22.06M | $24.05M | $26.35M | $21.43M | $21.58M | $14.27M | $10.16M | $15.66M | $17.57M | $26.25M | $39.25M | $40.98M | $20.5M | $12.34M | $17.3M | $5.93M | $3.7M | |
| -$21.76M | -$24.05M | -$26.35M | -$21.43M | -$21.58M | -$14.27M | -$10.16M | -$15.66M | -$17.57M | -$26.25M | -$39.25M | -$40.98M | -$20.5M | -$12.34M | -$17.3M | — | — | |
| — | -$23.94M | -$26.21M | -$21.3M | -$21.5M | -$14.19M | -$9.96M | -$15.42M | -$17.3M | -$26.01M | -$39.1M | -$40.91M | -$20.48M | -$12.3M | — | — | — | |
| $273K | $287K | $697K | $1.44M | $512K | $6000 | $44K | $283K | $67K | $21K | $37K | $6000 | $3000 | $33K | $33K | $14K | $0 | |
| $302K | $312K | $693K | $1.44M | $471K | $6000 | $44K | $283K | $4.15M | $10.76M | $11.45M | -$3.81M | $718K | $21K | $15K | -$1.7M | -$112K | |
| -$21.46M | -$23.74M | -$25.65M | -$19.99M | -$21.11M | -$14.27M | — | — | — | — | — | — | — | -$12.34M | -$17.3M | -$5.93M | -$1.08M | |
| — | — | $0 | -$1.64M | -$1.43M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$21.46M | -$23.74M | -$25.65M | -$18.35M | -$19.69M | -$14.27M | -$10.04M | -$15.3M | -$13.37M | -$15.17M | -$27.26M | -$43.74M | -$19.78M | -$12.32M | -$17.07M | -$8.15M | -$1.71M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -65.46% | |
| — | — | — | — | $0 | -$1000 | -$73K | -$77K | -$54K | -$318K | -$548K | -$1.05M | $0 | -$1000 | $0 | — | — | |
| -$22.97M | -$25.25M | -$25.65M | -$18.35M | -$20.03M | -$23.19M | -$12.56M | -$16.08M | -$25.29M | -$22.14M | -$27.26M | -$43.74M | — | — | — | — | — | |
| — | — | — | — | -$20.36M | -$14.27M | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$2.08 | -$19.03 | -$28.48 | -$32.75 | -$47.50 | -$165.00 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$2.08 | -$19.03 | -$28.48 | -$32.75 | -$47.50 | -$165.00 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 12.14M | 1.35M | 644.28K | 613.09K | 487.5K | 76.05K | 65.75K | 24.93K | 14.21K | 377.16K | 322.82K | 247.78K | 182.67K | 139.59K | 110.84K | — |
| shares | — | 12.14M | 1.35M | 644.28K | 613.09K | 487.5K | 76.05K | 65.75K | 24.93K | 14.21K | 377.16K | 322.82K | 247.78K | 182.67K | 139.59K | 110.84K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2014: $2M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.